WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

G GENITO URINARY SYSTEM AND SEX HORMONES
G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

Other hormones, see H - Systemic hormonal preparations, excl. sex hormones and insulins.
Sex hormones used only in the treatment of neoplastic diseases (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents.

The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability. The DDDs of depot preparations are calculated as the dose divided by the dosing interval.


G03B ANDROGENS

Anabolic steroids, see A14A. Norethandrolone, which has both anabolic and androgenic effects, is classified in A14A since the anabolic effect is considered to be the most important effect.
This group comprises male sex hormones. Combined preparations are included in this group, except combinations with female sex hormones, which are classified in G03E - Androgens and female sex hormones in combination.
The group is subdivided according to chemical structure.

The DDDs are based on use in substitution therapy in male hypogonadism. The DDDs for patches (e.g. testosterone) are given in amount delivered.


G03BA 3-oxoandrosten (4) derivatives

The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.


List of abbreviations

Last updated: 2024-01-26